financingCytovation ASA raises US$8m in Series ABergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing. more ➔ , more ➔
The innovative power of the chemical industry assembled The Chemspec Europe 2023 provided insights into current challenges of the chemical industry, as well as the solutions it holds. more ➔
autoimmunityStem cell gene transfer treats IL-1 immune diseasesItalian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice. more ➔
financingeXmoor Pharma Ltd raises US$35mBristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities. more ➔
financingVarmX BV raises €30m in Series B2 financingLeiden-based VarmX BV said it will use the €30m Series B2 money to complete the data required for IND approval of its lead candidate VMX-C001, a recombinante antidote to oral factor Xa inhibitors which … more ➔
immunoncologyGlioma drug combo turns tumours hotAn anti-TNF-antibody-cytokine fusion combo with chemotherapy turns inoperable brain tumours hot in mice. A Phase I trial sponsored by Philogen SpA is underway. more ➔
M&AVectivBio taken over in $1bn acquisitionGI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction. more ➔
AIAI predicts an enzyme’s substrateA new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology. more ➔
decarbonisationLanzaTech and Plastipak produce greener PETCarbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the world’s first PET resin made from captured carbon emissions. more ➔
Multiple sclerosisRoche’s meets endpoints in relapsing multiple sclerosisRoche’s bruton’s tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis. more ➔
